Expression levels of <i>WEE1</i> and <i>PARP1</i> in different DLBCL subgroups and in relation to anti-CD20 therapy with or without standard chemotherapy.

<p>(A) <i>WEE1</i> and (B) <i>PARP1</i> mRNA expression levels in Germinal Center B-cell (GCB, black), Activated B-cell (ABC, dark grey), and unclassified (light grey) Diffuse Large B-cell Lymphoma (DLBCL) samples. Overall survival for patients with DLBCL-GCB (C) and DLBCL-ABC (D) with low and high <i>WEE1</i> expression treated with CHOP or R-CHOP, and overall survival for DLBCL-GCB (E) and DLBCL-ABC (F) patients with low and high <i>PARP1</i> expression treated with CHOP or R-CHOP. Shown in the tables provided are the hazard ratios of adding anti-CD20 therapy with rituximab to standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)). Log-rank testing was used to test whether the curves are statistically different and to calculate the hazard ratio’s.